← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
ADCBiologicstaleEMD Serono Research & Developme…Phase 2

Tepotinib (Tepotinib)

Non-small Cell Lung Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 54.7%임상시험 28상태 ACTIVE
CGTBiologicstaleNanjing IASO Biotechnology Co.,…Phase 1

anti-CD19/CD22 CAR-T cells (anti-CD19/CD22 CAR-T cells)

MRD-positive; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 1%임상시험 28상태 ACTIVE
ADCBiologicstaleAmgenPhase 3

calaspargase pegol (calaspargase pegol)

B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma · NK-Cell Lymphoma

#NK-CellLymphoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 28상태 RECRUITING
ADCBiologicstaleAstellas Pharma IncPhase 2

ASG-22CE (ASG-22CE)

Bladder Cancer · Tumors

#Tumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 42.5%임상시험 27상태 ACTIVE
ADCBiologicstaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 71.7%임상시험 27상태 RECRUITING
ADCBiologicstaleZhenzhen LiuPreclinical

Herombopag (Herombopag)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 27상태 RECRUITING
ADCBiologicstaleAlessandro SantinPhase 2

IMGN853 (IMGN853)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 27상태 RECRUITING
ADCBiologicstaleAbbViePhase 1

IMGN853 (Mirvetuximab Soravtansine, Mirvetuximab Soravtansine (IMGN853))

Breast Cancer Triple Negative · Breast Cancer Triple Negative

#BreastCancerTripleNegative#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 27상태 DISCONTINUED
ADCBiologicstaleAbbViePhase 3

Mirvetuximab soravtansine (Mirvetuximab soravtansine)

Endometrial Cancer; Endometrial Adenocarcinoma · Ovarian Cancer

#OvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 27상태 ACTIVE
ADCBiologicstaleAbbViePhase 2

MIRV; IMGN853 (mirvetuximab soravtansine, mirvetuximab soravtansine (MIRV; IMGN853))

Ovarian Cancer; Fallopian Tube · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 100%임상시험 27상태 RECRUITING
CGTBiologicAmgenPhase 3

Avacopan (Avacopan)

Vasculitis · Vasculitis

#Vasculitis#CGT#Phase3#세포유전치료#CAR-T+3
임상시험 26상태 RECRUITING
ADCBiologicstaleLepu Medical Technology (Beijin…Phase 3

Becotatug Vedotin (Becotatug Vedotin)

Nasopharyngeal Carcinoma (NPC) · Adenoid Cystic Carcinoma

#AdenoidCysticCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 26상태 RECRUITING
ADCBiologicstaleSeagenPreclinical

brentuximab vedotin (Adcetris, Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine)

Anti-CD30; Brentuximab · CD30

#CD30#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 26상태 ACTIVE
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Drug: Disitamab Vedotin)

Upper Urinary Tract Urothelial Carcinoma · Upper Urinary Tract Urothelial Carcinoma

#UpperUrinaryTractUrothelialCarci#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 26상태 RECRUITING
AntibodystaleZhiyong YuPhase 2

Inetetamab (Inetetamab)

Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 26상태 ACTIVE
ADCBiologicstaleGBG Forschungs GmbHPhase 2

Phesgo (Phesgo)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 50%임상시험 26상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, albumin-bound paclitaxel+trastuzumab+pyrotinib)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 26상태 RECRUITING
ADCBiologicstaleBristol-Myers SquibbPhase 3

Amrubicin (Amrubicin)

Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 80%임상시험 25상태 RECRUITING
AntibodystaleRochePhase 2

CapeOX + bevacizumab (CapeOX + bevacizumab)

Unresectable Metastatic Colorectal Cancer; Microsatellite Stable (MSS) Colorectal Cancer (CRC) · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+4
임상시험 25상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING

37 / 209 페이지

← 이전다음 →